logo-loader
Arix Bioscience PLC

Arix Bioscience to invest another US$5mln in Autolus

Autolus said earlier this week it was looking to raise money from investors, and it has today confirmed plans to raise US$100.8mln through the issue of 4.2mln shares at US$24 each

dollars
Arix’s investment keeps its total stake in Autolus at 7.6%

Biotech investor Arix Bioscience PLC (LON:ARIX) has agreed to invest another £3.8mln (US$5.0mln) in Autolus Therapeutics PLC (NASDAQ:AUTL).

The share purchase will keep Arix’s stake in Autolus at 7.6%, which is valued at £62.6mln.

READ: Arix Bioscience confirms Autolus to launch proposed public offering

In total, Autolus is raising US$100.8mln from investors through the issue of 4.2mln American Depositary Shares (ADS) at US$24.00 apiece.

“Our investment in Autolus today demonstrates our strategy to build world-leading biotech companies through the provision of flexible, long term capital,” said chief executive Joe Anderson.

“We believe Autolus is at the forefront of a revolution in cancer treatment and that its innovative approach to T-cell programming has the potential to offer life-changing therapies for patients.”

Arix backing its winners

“Arix first invested £10mln into Autolus's Series B round in March 2016,” noted analysts at US investment bank Stifel.

“Subsequent financing rounds, the Nasdaq IPO in June 2018 and now this latest equity offering, means Arix has invested £24.6mln so far into Autolus.

“That investment is now valued at £62.6m generating a decent return so far, but with the market effectively discounting the shares during the offering (shares sold at US$24 per ADS vs US$31 per ADS before the offer was announced), we would expect the shares to recover and provide greater value uplift for Arix.”

Arix shares were down 1.3% to 144.1p on Thursday morning.

--Adds analyst comment--

Quick facts: Arix Bioscience PLC

Price: £1.12

Market: LSE
Market Cap: £151.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018

2 min read